Business Model Breakdown
How Insmed Inc Makes Money
INSM
Market Cap
$35.5B
Annual Revenue
$381M
Profit Margin
-210.5%
Employees
1,271
The Short Version
Insmed Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines for patients with rare diseases. It primarily generates revenue by selling its approved drugs to healthcare providers and specialty pharmacies for distribution to patients. Its current main products are ARIKAYCE, used to treat refractory Mycobacterium avium complex (MAC) lung disease, and BRINSUPRI (brensocatib), recently launched for non-cystic fibrosis bronchiectasis (NCFBE). The company is investing heavily in research and development to bring new therapies, like TPIP for idiopathic pulmonary fibrosis (IPF), to market.
Where the Revenue Comes From
ARIKAYCE sales (primary contributor pre-BRINSUPRI ramp-up)
BRINSUPRI (brensocatib) sales (rapidly growing post-launch)
Who buys: Patients with rare pulmonary diseases, prescribed by pulmonologists and other specialists; distributed through specialty pharmacies and healthcare systems.
Why It Works (Competitive Advantages)
- ✔First-in-class designation for BRINSUPRI in NCFBE (large unmet need)
- ✔Differentiated product profile for TPIP (once-daily treprostinil prodrug for IPF)
- ✔Established commercial infrastructure and expertise in rare pulmonary diseases with ARIKAYCE
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs, Efficient Scale)
What Our Analysis Says
DVR Score as of April 7, 2026
Insmed (INSM) exhibits strong potential for future market leadership through its innovative pipeline and growing commercial footprint, driving a high growth score. The successful U.S. launch of BRINSUPRI and positive Phase 3b results for ARIKAYCE's ENCORE study are significant de-risking events and catalysts for revenue expansion within substantial addressable markets (NCFBE, IPF). Analyst upgrades and robust institutional interest indicate growing market conviction. However, achieving 10x growth ($31B to $310B) is ambitious for an already large-cap company, requiring sustained multi-blockbuster success. Significant negative profitability metrics (Q4 EPS miss, -210.54% net margin, projected 2026 losses) and concerning heavy insider selling activity temper enthusiasm, despite a healthy balance sheet providing financial runway. Execution on commercial ramp-up and disciplined capital allocation will be critical for achieving exponential returns.